ISSN: 1859 - 2872
Prognostic value of ROX, SOFA, SAPS II and P/F score in assessing therapy of high-flow nasal cannula oxygen therapy among severe COVID-19 patients
Main Article Content
Keywords
Abstract
Objective: To find out the prognostic value of SOFA, SAPS II, P/F and ROX in assessing treatment the patients with severe COVID-19 with high-flow nasal cannula (HFNC) oxygen therapy. Subject and method: There were 109 patients with severe COVID-19 who received HFNC treatment at the National Hospital for Tropical Diseases from April 2021 to December 2023. Research method: Retrospective descriptive, data were collected retrospectively, through medical records. Result: The failure rate of HFNC was 49.6%. Lower P/F index, higher SAPS II score, higher SOFA score were prognostic factors for HFNC failure. An increase of 1 point in SAPS II score increased the risk of HFNC failure by 4 times (p=0.001). An increase in SOFA score of 1 point increased the risk of HFNC failure by 4.9 times (p<0.001). AUC analysis shows ROX index at 1 day after HFNC, P/F ratio at the time before and 1 day after HFNC were good predictors for successful HFNC with AUC (95%CI) of 0.849 (0.778-0.921), 0.877 (0.805-0.949), 0.898 (0.833-0.962), respectively. Conclusion: ROX index, SOFA, SAPS II scores and P/F ratio showed the effectiveness to predict mortality in severe COVID-19 patients using HFNC.
Article Details
References
2. Le Pape S, Savart S, Arrivé F et al (2023) High-flow nasal cannula oxygen versus conventional oxygen therapy for acute respiratory failure due to COVID-19: a systematic review and meta-analysis. Annals of Intensive Care 13(1): 114.
3. Xu J, Yang X, Huang C et al (2020) A novel risk-stratification models of the high-flow nasal cannula therapy in COVID-19 patients with hypoxemic respiratory failure. Frontiers in Medicine 7:607821. doi: 10.3389/fmed.2020.607821.
4. Luo MS, Huang GJ, and Wu L (2019) High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure. Intensive Care Medicine 45(8): 1167-1168.
5. Basoulis D, Avramopoulos P, Aggelara M et al (2023) Validation of sequential ROX-Index score beyond 12 hours in predicting treatment failure and mortality in COVID-19 patients receiving oxygen via high-flow nasal cannula. Can Respir J: 7474564.
6. Alshahrani MS, Alshaqaq HM, Alhumaid J et al (2021) High-flow nasal cannula treatment in patients with COVID-19 acute hypoxemic respiratory failure: A Prospective cohort study. Saudi J Med Med Sci 9(3): 215-222.
7. Kim JH, Baek AR, Lee SI et al (2022) ROX index and SpO2/FiO2 ratio for predicting high-flow nasal cannula failure in hypoxemic COVID-19 patients: A multicenter retrospective study. PLoS One 17(5): e0268431.
8. Hu M, Zhou Q, Zheng R et al (2020) Application of high-flow nasal cannula in hypoxemic patients with COVID-19: A retrospective cohort study. BMC Pulm Med 20(1): 324.
9. Duan J, Zeng J, Deng P et al (2021) High-flow nasal cannula for COVID-19 patients: A multicenter retrospective study in China. Front Mol Biosci 8: 639100.
Article Sidebar
